会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明授权
    • Methods for producing self-replicating infectious RSV particles comprising recombinant RSV genomes or antigenomes and the N, P, L, and M2 proteins
    • 用于产生包含重组RSV基因组或抗原单核细胞和N,P,L和M2蛋白质的自复制感染性RSV颗粒的方法
    • US06790449B2
    • 2004-09-14
    • US09847173
    • 2001-05-03
    • Peter L. Collins
    • Peter L. Collins
    • A61K39155
    • C07K14/005A61K39/00A61K2039/525C12N7/00C12N15/86C12N2760/18521C12N2760/18522C12N2760/18543
    • RNA synthesis by the paramyxovirus respiratory syncytial virus (RSV), a ubiquitous human pathogen, was found to be more complex than previously appreciated for the nonsegmented negative-strand RNA viruses. Intracellular RNA replication of a plasmid-encoded “minigenome” analog of viral genomic RNA was directed by coexpression of the nucleocapsid (N) protein, nucleocapsid phosphoprotein (P), and the large polymerase (L) protein. But, under these conditions, it appeared that the greater part of mRNA synthesis terminated prematurely. However, coexpression of the M2 (ORF1) gene resulted in the efficient production of full-length mRNA. Thus, these results demonstrate that expression of the upstream ORF1, which encoded the previously described 22-kDa M2 protein, was associated with transcription elongation. Accordingly, the claimed invention is directed toward infectious recombinant RSV particles which comprise a recombinant genome or antigenome, as well as the RSV proteins N, P, L, and the RNA polymerase elongation factor M2. This system will permit the introduction of defined changes into infectious RSV which will prove useful in a variety of applications, such as the analysis of RSV molecular biology and pathogenesis, the development of attenuated RSV immunogenic compositions for the preparation of RSV-specific immunological reagents, and the expression of foreign antigens.
    • 发现通过普遍存在的人类病原体的副粘病毒呼吸道合胞病毒(RSV)的RNA合成比以前对非分段负链RNA病毒所认识的更为复杂。 病毒基因组RNA的质粒编码的“小基因组”类似物的细胞内RNA复制通过核衣壳(N)蛋白,核壳蛋白磷蛋白(P)和大聚合酶(L)蛋白的共表达来引导。 但是,在这些条件下,mRNA合成的较大部分似乎过早终止。 然而,M2(ORF1)基因的共表达导致全长mRNA的有效产生。 因此,这些结果表明编码前述的22-kDa M2蛋白的上游ORF1的表达与转录延伸有关。 因此,要求保护的发明涉及包含重组基因组或反向原子团以及RSV蛋白N,P,L和RNA聚合酶延伸因子M2的感染性重组RSV颗粒。 该系统将允许将感染性RSV引入定义的变化,这将在各种应用中有用,例如RSV分子生物学和发病机理的分析,用于制备RSV特异性免疫试剂的减毒RSV免疫原性组合物的开发, 和外源抗原的表达。
    • 3. 发明授权
    • Enhanced immune response to attachment (G) protein of Respiratory Syncytial Virus
    • 增强对呼吸道合胞病毒附着(G)蛋白的免疫反应
    • US06699478B1
    • 2004-03-02
    • US09526195
    • 2000-03-15
    • Gerald E. HancockPaul W. Tebbey
    • Gerald E. HancockPaul W. Tebbey
    • A61K39155
    • C07K14/005A61K39/00A61K2039/51C07K2319/00C12N2760/18522
    • An altered G protein or portion thereof of RSV which retains immunogenicity and which, when incorporated into an immunogenic composition or vaccine and administered to a vertebrate, does not induce enhanced disease (e.g., atypical pulmonary inflammation such as pulmonary eosinophilia) upon subsequent infection with RSV, is disclosed. In a particular embodiment, the altered G protein comprises an alteration in one or more regions selected from the group consisting of the region from amino acid 159 to amino acid 198, the region from amino acid 159 to amino acid 174, the region from amino acid 171 to amino acid 187, the region from amino acid 176 to amino acid 190, and the region from amino acid 184 to amino acid 198 of the RSV G protein. Immunogenic compositions and vaccines comprising the altered RSV G protein, and optionally comprising RSV F protein, are also disclosed.
    • 维持免疫原性的改变的G蛋白或其部分,并且当其并入免疫原性组合物或疫苗并且施用于脊椎动物时,在随后的RSV感染时不诱导增强的疾病(例如非典型的肺部炎症,例如肺嗜酸性粒细胞增多) ,被披露。 在一个具体实施方案中,改变的G蛋白包括在一个或多个区域中的改变,所述区域选自氨基酸159至氨基酸198的区域,氨基酸159至氨基酸174的区域,氨基酸的区域 171至氨基酸187,氨基酸176至氨基酸190的区域,以及RSV G蛋白的氨基酸184至氨基酸198的区域。 还公开了包含改变的RSV G蛋白和任选地包含RSV F蛋白的免疫原性组合物和疫苗。
    • 10. 发明授权
    • Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins
    • 编码牛呼吸道合胞病毒免疫原性蛋白的核苷酸序列
    • US06730305B1
    • 2004-05-04
    • US09567458
    • 2000-05-08
    • Gail W. WertzRobert Lerch
    • Gail W. WertzRobert Lerch
    • A61K39155
    • C07K14/005A61K38/00A61K39/00A61K39/12A61K39/155A61K2039/5256C12N2710/24143C12N2760/18522C12N2760/18534
    • The present invention relates to recombinant DNA molecules which encode bovine respiratory syncytial (BRS) virus proteins, to BRS virus proteins, and peptides and to recombinant BRS virus vaccines produced therefrom. It is based, in part, on the cloning of substantially full length cDNAs which encode the entire BRS virus G, F, and N proteins. According to particular embodiments of the invention, DNA encoding a BRS virus protein or peptide may be used to diagnose BRS virus infection, or, alternatively, may be inserted into an expression vector, including, but not limited to, vaccinia virus as well as bacterial, yeast, insect, or other vertebrate vectors. These expression vectors may be utilized to produce the BRS virus protein or peptide in quantity; the resulting substantially pure viral peptide or protein may be incorporated into subunit vaccine formulations or may be used to generate monoclonal or polyclonal antibodies which may be utilized in diagnosis of BRS virus infection or passive immunization. In additional embodiments, BRS virus protein sequence provided by the invention may be used to produce synthetic peptides or proteins which may be utilized in subunit vaccines, or polyclonal or monoclonal antibody production. Alternatively, a nonpathogenic expression vector containing the genes, parts of the genes, any combination of the genes, or parts thereof may itself be utilized as a recombinant virus vaccine.
    • 本发明涉及编码牛呼吸道合胞体(BRS)病毒蛋白质,BRS病毒蛋白质的重组DNA分子,以及由其产生的重组BRS病毒疫苗。 其部分基于克隆编码整个BRS病毒G,F和N蛋白的基本上全长的cDNA。 根据本发明的具体实施方案,编码BRS病毒蛋白或肽的DNA可用于诊断BRS病毒感染,或者可以将其插入到表达载体中,包括但不限于痘苗病毒以及细菌 ,酵母,昆虫或其他脊椎动物载体。 这些表达载体可以用来量产BRS病毒蛋白或肽; 所得到的基本上纯的病毒肽或蛋白质可以并入亚单位疫苗制剂中,或可用于产生可用于诊断BRS病毒感染或被动免疫的单克隆或多克隆抗体。 在另外的实施方案中,本发明提供的BRS病毒蛋白质序列可用于产生可用于亚单位疫苗或多克隆或单克隆抗体产生的合成肽或蛋白质。 或者,含有基因,部分基因,基因的任何组合或其部分的非致病性表达载体本身可以用作重组病毒疫苗。